Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

By M. Duvic, K. Hymes, Peter D. Heald, D. Breneman, Ann G. Martin, P. Myskowski, C. Crowley, R. Yocum. Journal of Clinical Oncology, 2001

690 citations recorded by the source corpus.

Subfields: Dermatology, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/376d91e14144ddc8ac433c88dd7f8b9e31f71686

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. T. Kuzel
2. T. Pacheco
3. F. Foss
4. S. Parker
5. Cong Chen
6. S. Frankel
7. E. Olsen
8. J. Arduino

Citations in the corpus

• Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. (2007, background): “In patients with stage IIB or higher MF/SS who had received two or more prior systemic therapies, a conservative estimate of the maximum spontaneous response rate was 5%.(20) Vorinostat would be considered active for MF/SS treatment if the observed response rate was 20% with the lower bound of the 9”
• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). (2007, neutral): “Dehydration 6 (16) 1 (3) 2 (5) 1 (3) 2 (5)”